Spanish researchers developed a new type of protein biomaterial that allows a continuous and gradual release of therapeutic proteins when administered subcutaneously in laboratory animals. The study is signed by researchers from the Biomedical Research Center in Network for Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB) and the Research Institute of the Hospital of San Pablo. The study was published in Advanced Science.

These structures, of a few micrometers in diameter, contain functional proteins that are released in a similar way to the release of human hormones in the endocrine system,” says Antonio Villaverde , a CIBER-BBN and IBB-UAB researcher and one of the coordinators of the work.

Ramón Mangues , from the Research Institute of the Hospital of San Pablo, a researcher at CIBER-BBN and co-author of the work, explains that “the new biomaterial mimics a common bacterial product in biotechnological processes called inclusion bodies, of pharmacological interest; which in this artificial version, offers a wide range of therapeutic possibilities in the field of oncology and in any other clinical setting that requires continuous [drug] release over time.”

Long acting antitumor

Researchers used common enzymes in biotechnology as a model and a nanostructured bacterial toxin that targets metastatic cells of human colorectal cancer, which has been tested in animal models. “In this way we have managed to generate both immobilized catalysts and a new long-acting anti-tumor drug,” said the authors.

The artificial protein granules, which had previously been proposed as nanopills, mimic bacterial inclusion bodies and offer great clinical potential in the field of vaccinology and as controlled drug release systems.

 

Source: Correo Farmacéutico